Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Neurimmune

Tracked across 3 events · 19 articles · First seen Jun 24, 2026 · Last active Sep 02, 2026

Sentiment
30
Attention
6
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
3 30
Business
Impact: Neurimmune receives up to $425 million in exchange for a portion of its royalty interest, providing funds to advance its R&D pipeline while retaining majority royalty and milestone interests.
Jul 22, 2026 · 7 articles
2 60
Business
Impact: Neurimmune co-led the financing and is a strategic partner, having discovered the anti-Nogo-A antibody NG004. Its involvement validates the science and deepens its stake in NovaGo's success.
Jul 20, 2026 · 6 articles
6 0
Tech
Impact: Neurimmune is a co-owner of ALS Pharma, contributing to the development of IBM System/4 Pi.
Jun 24, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Neurimmune live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.